Inotiv, Inc.

Inotiv, Inc. (NOTV) is a US-listed equity tracked across major market indices. Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.

The company reports trailing twelve-month revenue of $151.46M and net loss of $32.47M. Key metrics include a return on equity of -42.1%, a debt-to-equity ratio of 8.11.

FINOTAUR provides free research summaries, news aggregation, and fundamentals for NOTV to support both active traders and long-term investors.